Edwards Lifesciences Corporation (EW)

Market Cap	52.46B
Revenue (ttm)	6.00B
Net Income (ttm)	1.40B
Shares Out	601.30M
EPS (ttm)	2.30
PE Ratio	37.93
Forward PE	30.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,768,000
Open	89.89
Previous Close	90.05
Day's Range	86.45 - 89.63
52-Week Range	60.57 - 96.12
Beta	1.07
Analysts	Buy
Price Target	92.82 (+6.4%)
Earnings Date	Apr 25, 2024

About EW

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical struct...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 27, 2000
• Employees: 19,800
• Stock Exchange: NYSE
• Ticker Symbol: EW

Financial Performance

In 2023, EW's revenue was $6.00 billion, an increase of 11.56% compared to the previous year's $5.38 billion. Earnings were $1.40 billion, a decrease of -7.85%.

Analyst Forecast

According to 18 analysts, the average rating for EW stock is "Buy." The 12-month stock price forecast is $92.82, which is an increase of 6.40% from the latest price.

Price Target

$92.82

(6.40% upside)

Analyst Consensus: Buy